European Spine Journal

, Volume 12, Supplement 2, pp S147–S154

The aging spine: new technologies and therapeutics for the osteoporotic spine

  • Joseph M. Lane
  • Michael J. Gardner
  • Julie T. Lin
  • Marjolein C. van der Meulen
  • Elizabeth Myers
Review

Abstract

Osteoporosis results in low-energy fractures of the spine. The load necessary to cause a vertebral fracture is determined by the characteristics related to the vertebral body structure, mineral content, and quality of bone. Radiographic techniques centered on dual X-ray absorptiometry (DXA) permit a determination of bone mass and fracture risk. Current medical therapies principally using bisphosphonate and pulsatile PTH profoundly decrease the risk of fracture (50+%). Fall prevention strategies can further decrease the possibility of fracture. A comprehensive approach to osteoporosis can favorably alter the disease.

Keywords

Vertebral fracture Osteoporosis Bisphosphonates PTH (1–34) Falls 

References

  1. 1.
    Adami S, Prizzi R, Colapietro F (2001). Alendronate for the treatment of osteoporosis in men. Calcif Tissue Int 69:239–241CrossRefPubMedGoogle Scholar
  2. 2.
    Arnaud CD (1996) Osteoporosis: using ‘bone markers’ for diagnosis and monitoring. Geriatrics 51:24–30Google Scholar
  3. 3.
    Bagur A, Solis F, Di Gregorio S, Mautalen C (2000) Reference data of vertebral morphometry by X-ray absorptiometry (MXA) in Argentine women. Calcif Tissue Int 66:259–262CrossRefPubMedGoogle Scholar
  4. 4.
    Baylink DJ (2000) The diagnosis and management of osteoporosis. J Rheumatol 59 [Suppl 1]:42–44Google Scholar
  5. 5.
    Bianco AC, Malvestiti LF, Gouveia CH, Wehba S, Lewin S, Marone MM (1999) Morphometric dual-energy X-ray absorptiometry of the spine: report of a large series and correlation with axial bone mineral density. J Bone Miner Res 14:1605–1613PubMedGoogle Scholar
  6. 6.
    Bidwell J, Feister H, Swartz D, Onyia J, Holden J, Hock J (1996) Parathyroid hormone regulates the expression of rat osteoblast and osteosarcoma nuclear matrix proteins. J Cell Biochem 63:374–383PubMedGoogle Scholar
  7. 7.
    Black DM, Cummings SR, Karpf DB, et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedGoogle Scholar
  8. 8.
    Body JJ, Gaich GA, Scheele WH, et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528–4535CrossRefPubMedGoogle Scholar
  9. 9.
    Carter DR, Hayes WC (1977) The compressive behavior of bone as a two-phase porous structure J Bone Joint Surg Am 59:954–962Google Scholar
  10. 10.
    Carter DR, Bouxsein ML, Marcus R (1992) New approaches for interpreting projected bone densitometry data. J Bone Miner Res 7:137–145PubMedGoogle Scholar
  11. 11.
    Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561CrossRefPubMedGoogle Scholar
  12. 12.
    Cauley JA, Norton L, Lippman ME, et al (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125–134CrossRefPubMedGoogle Scholar
  13. 13.
    Chausmer AB (2001) Bone density measurement techniques in the diagnosis and management of osteoporosi. J S C Med Assoc 97:106–110PubMedGoogle Scholar
  14. 14.
    Chavassieux PM, Arlot ME, Roux JP, et al (2000) Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 15:754–762PubMedGoogle Scholar
  15. 15.
    Chestnut CH 3rd, Silverman S, Adriano K, Genant H (2002) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med 109:267–276CrossRefGoogle Scholar
  16. 16.
    Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S-17S; discussion 17S-19SGoogle Scholar
  17. 17.
    Crandall C (2002) Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 162:2297–2309CrossRefPubMedGoogle Scholar
  18. 18.
    Cummings SR, Black DM, Thompson DE, et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMedGoogle Scholar
  19. 19.
    Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670–676Google Scholar
  20. 20.
    Delmas PD, Ensrud KE, Adachi JD, et al (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617Google Scholar
  21. 21.
    Dickler MN, Norton L (2001) The MORE trial: multiple outcomes for raloxifene evaluation—breast cancer as a secondary end point: implications for prevention. Ann N Y Acad Sci 949:134–142PubMedGoogle Scholar
  22. 22.
    Doggrell SA (2002) Zoledronate once-yearly increases bone mineral density — implications for osteoporosis. Expert Opin Pharmacother 3:1007–1009PubMedGoogle Scholar
  23. 23.
    Ensrud KE, Thompson DE, Cauley JA, et al (2000) Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 48:241–249PubMedGoogle Scholar
  24. 24.
    Ettinger B, Black DM, Mitlak BH, et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645PubMedGoogle Scholar
  25. 25.
    Ferrar L, Jiang G, Barrington NA, Eastell R (2000) Identification of vertebral deformities in women: comparison of radiological assessment and quantitative morphometry using morphometric radiography and morphometric X-ray absorptiometry. J Bone Miner Res 15:575–585PubMedGoogle Scholar
  26. 26.
    Ferrar L, Jiang G, Eastell R (2001) Longitudinal evaluation of morphometric X-ray absorptiometry for the identification of vertebral deformities. Osteoporos Int 12:661–671CrossRefPubMedGoogle Scholar
  27. 27.
    Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM (1998) Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1–34): a randomized controlled trial. JAMA 280:1067–1073CrossRefPubMedGoogle Scholar
  28. 28.
    Follin SL, Black JN, McDermott MT (2003) Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy 23:190–198PubMedGoogle Scholar
  29. 29.
    Fujita T, Inoue T, Morii H, et al (1999) Effect of an intermittent weekly dose of human parathyroid hormone (1–34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 9:296–306CrossRefPubMedGoogle Scholar
  30. 30.
    Galante J, Rostoker W, Ray RD (1970) Physical properties of trabecular bone. Calcif Tis Res 5:236–246Google Scholar
  31. 31.
    Gardner MJ, Flik KR, Mooar P, Lane JM (2002) Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surg Am 84:1342–1348Google Scholar
  32. 32.
    Gass R (2001) The early preclinical diagnosis of osteoporosis measuring the pure trabecular bone density. Eur J Med Res 6:228–230PubMedGoogle Scholar
  33. 33.
    Geusens P, Autier P, Boonen S, Vanhoof J, Declerck K, Raus JN (2002) The relationship among history of falls, osteoporosis, and fractures in postmenopausal women. Arch Phys Med Rehabil 83:903–906CrossRefPubMedGoogle Scholar
  34. 34.
    Giannoukos G, Williams LJ, Chilco PJ, Abou-Samra AB (1999) Characterization of an element within the rat parathyroid hormone/parathyroid hormone-related peptide receptor gene promoter that enhances expression in osteoblastic osteosarcoma 17/2.8 cells. Biochem Biophys Res Commun 258:336–340CrossRefPubMedGoogle Scholar
  35. 35.
    Gonnelli S, Cepollaro C, Montagnani A, et al (2003) Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue IntGoogle Scholar
  36. 36.
    Grados F, Fardellone P, Benammar M, Muller C, Roux C, Sebert JL (1999) Influence of age and sex on vertebral shape indices assessed by radiographic morphometry. Osteoporos Int 10:450–455CrossRefPubMedGoogle Scholar
  37. 37.
    Greenspan SL, von Stetten E, Emond SK, Jones L, Parker RA (2001) Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. J Clin Densitom 4:373–380PubMedGoogle Scholar
  38. 38.
    Greenspan SL, Bone G 3rd, Schnitzer TJ, et al (2002) Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17:1988–1996PubMedGoogle Scholar
  39. 39.
    Guermazi A, Mohr A, Grigorian M, Taouli B, Genant HK (2002) Identification of vertebral fractures in osteoporosis. Sem Musculoskeletal Radiol 6:241–252CrossRefGoogle Scholar
  40. 40.
    Harris ST, Watts NB, Genant HK, et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedGoogle Scholar
  41. 41.
    Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O (2003) Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 14:61–68PubMedGoogle Scholar
  42. 42.
    Hayes WC, Myers ER, Robinovitch SN, van den Kroonenberg A, Courtney A, McMahon T (1996) Etiology and prevention of age-related hip fracturesGoogle Scholar
  43. 43.
    Heijckmann AC, Juttmann JR, Wolffenbuttel BH (2002) Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med 60:315–319PubMedGoogle Scholar
  44. 44.
    Holzer G, Majeska RJ, Lundy MW, Hartke JR, Einhorn TA (1999) Parathyroid hormone enhances fracture healing. A preliminary report. Clin Orthop 258–263Google Scholar
  45. 45.
    Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF (2003) Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569–575CrossRefPubMedGoogle Scholar
  46. 46.
    Ito M, Tsurusaki K, Hayashi K (1997) Peripheral QCT for the diagnosis of osteoporosis. Osteoporos Int 7 [Suppl 3]:120–127Google Scholar
  47. 47.
    Jahng JS, Kim HW (2000) Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats. Orthopedics 23:1089–1094PubMedGoogle Scholar
  48. 48.
    Jalava T, Sarna S, Pylkkanen L, et al (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18:1254–1260PubMedGoogle Scholar
  49. 49.
    Jordan KM, Cooper C (2002) Epidemiology of osteoporosis Best Pract Res Clin Rheumatol 16:795–806CrossRefGoogle Scholar
  50. 50.
    Kado DM, Duong T, Stone KL, Ensrud KE, et al (2003) Incident vertebral fractures and mortality in older women: a prospective study. Osteoporosis Int 14:589–594Google Scholar
  51. 51.
    Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936CrossRefPubMedGoogle Scholar
  52. 52.
    Kelly CM, Wilkins RM, Gitelis S, Hartjen C, Watson JT, Kim PT (2001) The use of a surgical grade calcium sulfate as a bone graft substitute: results of a multicenter trial. Clin Orthop 42–50Google Scholar
  53. 53.
    Kessenich CR (1998) Tai Chi as a method of fall prevention in the elderly. Orthop Nurs 17:27–29Google Scholar
  54. 54.
    Lane JM (1997) Osteoporosis. Medical prevention and treatment. Spine 22:32S-37SCrossRefPubMedGoogle Scholar
  55. 55.
    Lane JM, Nydick M (1999) Osteoporosis: current modes of prevention and treatment. J Am Acad Orthop Surg 7:19–31PubMedGoogle Scholar
  56. 56.
    Lieberman JR, Le LQ, Wu L, et al (1998) Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 16:330–339PubMedGoogle Scholar
  57. 57.
    Liberman UA, Weiss SR, Broll J, et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443PubMedGoogle Scholar
  58. 58.
    Lin JT, van der Meulen MCH, Myers ER, Lane JM (2003) Fracture evaluation and clinical complications. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 5th edn. (in press)Google Scholar
  59. 59.
    Lin JT, Backus S, Meyers E, Peterson M, Lane JM (2003) Six minute walk test: a new powerful predictor of functional dysfunction in osteoporotic patients with and without vertebral fractures (abstract). J Bone Min Res (in press)Google Scholar
  60. 60.
    Lindsay R, Hart DM, Forrest C, Baird C (1980) Prevention of spinal osteoporosis in oophorectomised women. Lancet 2:1151–1154PubMedGoogle Scholar
  61. 61.
    Lindsay R, Silverman SL, Cooper C, Hanley DA, et al (2002) Risk of new vertebral fracture in the year following fracture. JAMA 17:285:320–323Google Scholar
  62. 62.
    Liu G, Peacock M, Eilam O, Dorulla G, Braunstein E, Johnston CC (1997) Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos Int 7:564–569PubMedGoogle Scholar
  63. 63.
    Lofman O, Larsson L, Toss G (2000) Bone mineral density in diagnosis of osteoporosis: reference population, definition of peak bone mass, and measured site determine prevalence. J Clin Densitom 3:177–186Google Scholar
  64. 64.
    Looker AC, Johnston CC Jr, Wahner HW, et al Prevalence of low femoral bone density in older US women from NHANES III (1995) J Bone Miner Res 10:796–802PubMedGoogle Scholar
  65. 65.
    Luckey MM, Gilchrist N, Bone HG, et al (2003) Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol 101:711–721CrossRefPubMedGoogle Scholar
  66. 66.
    Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259PubMedGoogle Scholar
  67. 67.
    Matthis C, Weber U, O’Neill TW, Raspe H (1998) Health impact associated with vertebral deformities: results from the European Vertebral Osteoporosis Study (EVOS). Osteoporos Int 8:364–372CrossRefPubMedGoogle Scholar
  68. 68.
    Melton LJ 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL (1992) Perspective. How many women have osteoporosis? J Bone Miner Res 7:1005–1010PubMedGoogle Scholar
  69. 69.
    Melton LJ 3rd, Atkinson EJ, Cooper C, O’Fallon WM, Riggs BL (1999) Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214–221CrossRefPubMedGoogle Scholar
  70. 70.
    Miller PD (2001) New possibilities for diagnosis and treatment of osteoporosis. Int J Fertil Womens Med 46:215–221PubMedGoogle Scholar
  71. 71.
    Moro M, Hecker AT, Bouxsein ML, Myers ER (1995) Failure load of thoracic vertebrae correlates with lumbar bone mineral density measured by DXA. Calcif Tissue Int 56:206–209PubMedGoogle Scholar
  72. 72.
    Nakajima A, Shimoji N, Shiomi K, et al (2002) Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1–34). J Bone Miner Res 17:2038–2047PubMedGoogle Scholar
  73. 73.
    Neer RM, Arnaud CD, Zanchetta JR, et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedGoogle Scholar
  74. 74.
    Neuner JM, Zimmer JK, Hamel MB (2003) Diagnosis and treatment of osteoporosis in patients with vertebral compression fractures. J Am Geriatr Soc 51:483–491PubMedGoogle Scholar
  75. 75.
    Nordin BE, Morris HA (1989) The calcium deficiency model for osteoporosis. Nutr Rev 47:65–72PubMedGoogle Scholar
  76. 76.
    O’Gradaigh D, Debiram I, Love S, Richards HK, Compston JE (2003) A prospective study of discordance in diagnosis of osteoporosis using spine and proximal femur bone densitometry. Osteoporos Int 14:13–18PubMedGoogle Scholar
  77. 77.
    Okazaki K, Jingushi S, Ikenoue T, Urabe K, Sakai H, Iwamoto Y (2003) Expression of parathyroid hormone-related peptide and insulin-like growth factor I during rat fracture healing. J Orthop Res 21:511–520CrossRefPubMedGoogle Scholar
  78. 78.
    Orwoll E, Ettinger M, Weiss S, et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610PubMedGoogle Scholar
  79. 79.
    Osteoporosis prevention, diagnosis, and therapy (2000) NIH Consensus Statement 17:1–45Google Scholar
  80. 80.
    Owens JM, Fuller K, Chambers TJ (1997) Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. J Cell Physiol 172:79–86CrossRefPubMedGoogle Scholar
  81. 81.
    Paganini-Hill A, Chao A, Ross RK, Henderson BE (1991) Exercise and other factors in the prevention of hip fracture: the Leisure World study. Epidemiology 2:16–25PubMedGoogle Scholar
  82. 82.
    Park J, Ries J, Gelse K, et al (2003) Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. Gene Ther 10:1089–1098CrossRefPubMedGoogle Scholar
  83. 83.
    Pasquini GM, Davey RA, Ho PW, et al (2002) Local secretion of parathyroid hormone-related protein by an osteoblastic osteosarcoma (UMR 106–01) cell line results in growth inhibition. Bone 31:598–605CrossRefPubMedGoogle Scholar
  84. 84.
    Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA (1996) Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14:74–79PubMedGoogle Scholar
  85. 85.
    Rea JA, Chen MB, Li J, et al (2000) Morphometric X-ray absorptiometry and morphometric radiography of the spine: a comparison of prevalent vertebral deformity identification. J Bone Miner Res 15:564–574PubMedGoogle Scholar
  86. 86.
    Rea JA, Chen MB, Li J, et al (2001) Vertebral morphometry: a comparison of long-term precision of morphometric X-ray absorptiometry and morphometric radiography in normal and osteoporotic subjects. Osteoporos Int 12:158–166CrossRefPubMedGoogle Scholar
  87. 87.
    Recker RR, Hinders S, Davies KM, et al (1996) Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 11:1961–1966PubMedGoogle Scholar
  88. 88.
    Riew KD, Wright NM, Cheng S, Avioli LV, Lou J (1998) Induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene in a rabbit spinal fusion model. Calcif Tissue Int 63:357–360Google Scholar
  89. 89.
    Ross PD (1996) Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med 156:1399–1411PubMedGoogle Scholar
  90. 90.
    Saag KG, Emkey R, Schnitzer TJ, et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299CrossRefPubMedGoogle Scholar
  91. 91.
    Sahota O(2000) Osteoporosis and the role of vitamin D and calcium-vitamin D deficiency, vitamin D insufficiency, and vitamin D sufficiency. Age Ageing 29:301–304CrossRefPubMedGoogle Scholar
  92. 92.
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10PubMedGoogle Scholar
  93. 93.
    Schousboe JT, DeBold CR, Bowles C, Glickstein S, Rubino RK (2002) Prevalence of vertebral compression fracture deformity by X-ray absorptiometry of lateral thoracic and lumbar spines in a population referred for bone densitometry. J Clin Densitom 5:239–246PubMedGoogle Scholar
  94. 94.
    Shields AT, Chesnut CH 3rd (2001) Diagnosis of postmenopausal osteoporosis: reviews in endocrine and metabolic disorders. Rev Endocr Metab Disord 2:23–33CrossRefPubMedGoogle Scholar
  95. 95.
    Simkin A, Ayalon J, Leichter I (1987) Increased trabecular bone density due to bone-loading exercises in postmenopausal osteoporotic women. Calcif Tissue Int 40:59–63PubMedGoogle Scholar
  96. 96.
    Stephenson J (2003) FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA 289:537–538CrossRefPubMedGoogle Scholar
  97. 97.
    Strocchi R, Orsini G, Iezzi G, et al (2002) Bone regeneration with calcium sulfate: evidence for increased angiogenesis in rabbits. J Oral Implantol 28:273–278PubMedGoogle Scholar
  98. 98.
    Tinetti ME, Baker DI, Garrett PA, Gottschalk M, Koch ML, Horwitz RI (1993) Yale FICSIT: risk factor abatement strategy for fall prevention. J Am Geriatr Soc 41:315–320PubMedGoogle Scholar
  99. 99.
    Varady P, Li JZ, Alden TD, Kallmes DF, Williams MB, Helm GA (2002) CT and radionuclide study of BMP-2 gene therapy-induced bone formation. Acad Radiol 9:632–637PubMedGoogle Scholar
  100. 100.
    Wolf SL, Barnhart HX, Kutner NG, McNeely E, Coogler C, Xu T (1996) Reducing frailty and falls in older persons: an investigation of Tai Chi and computerized balance training. Atlanta FICSIT Group. Frailty and injuries: cooperative studies of intervention techniques. J Am Geriatr Soc 44:489–497PubMedGoogle Scholar
  101. 101.
    Wu G (2002) Evaluation of the effectiveness of Tai Chi for improving balance and preventing falls in the older population — a review. J Am Geriatr Soc 50:746–754CrossRefPubMedGoogle Scholar
  102. 102.
    Zerath E, Holy X, Noel B, Malouvier A, Hott M, Marie PJ (1998) Effects of BMP-2 on osteoblastic cells and on skeletal growth and bone formation in unloaded rats. Growth Horm IGF Res 8:141–149Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Joseph M. Lane
    • 1
    • 2
  • Michael J. Gardner
    • 1
  • Julie T. Lin
    • 1
  • Marjolein C. van der Meulen
    • 1
  • Elizabeth Myers
    • 1
  1. 1.Metabolic Bone Disease ServiceHospital for Special SurgeryNew YorkUSA
  2. 2.Department of Orthopaedic SurgeryHospital for Special SurgeryNew YorkUSA

Personalised recommendations